Vectura has agreed to a £1.55 per share takeover by US private investment company Carlyle, which values the UK drug delivery specialist at £958 million ($1.4 billion).
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.